Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
'Everybody happy with a £1?' - very reminiscent of the old guard who would propose something, talk about it for a bit, then say 'We are all agreed....'
Any 'final' price relies on the assumption there will be a buyout, so a big string of 'ifs.' Very tiresome.
It's probably worth clarifying a couple of things which keep cropping up and tend to get a little distorted at times - one is that Redmile (and Vulpes and Calculus) are not quick buck fly-by-night setups. If they consider today's share price 'derisory' then imo they are not likely to grab the first low ball offer that pops up, especially given the recent progress and quality of the current trials. The data is very good, and expected to increase in quality and volume. Not the point to bale out I would say.
Second point where the basic facts seem to get ignored - if Redmile's holding does go over 30 percent, yes they are required to make an offer for the whole company. However, the board and shareholders are not obliged to accept it, in which case Redmile simply carry on with an increased shareholding. There seems to be a mentality that promotes the idea that crossing the 30 percent holding means an immediate buyout at a low price. Wrong.
Sit back, relax, enjoy the ride folks.
I bet they don't manage to string out calling an EGM for two and a half years like they have with the TheoremRx farce. So at least that will be proof they can meet a deadline when under pressure.
If ever an RNS was announced through gritted teeth, this is it.
Presumably the Little Soap Company does beauty products for some of those elderly mice.
C11 - probably as he finds it hard to be objective with all those splinters in his posterior from sitting on the fence and gyrating every which way.
The other problem with the LOI is that it gave exclusivity, which means a guarantee that it was Theorem or nobody. Maybe Black Cat will pop up with the 5 million they were going to raise instead. That was another one that was announced and then never heard from again.
C11 - same reason he's always been here I suppose.
If it wasn't for the three 125:1 consolidations I calculate they'd have around 257,812,500,000,000 shares in issue.
The abusive retort doesn't exactly cement your status as a provider of informed prediction. So, a guess. What do you guess this RNS will contain? Board resignations? Difficult trading conditions? Major deal worth billions? Theorem LOI cut into four and hung in the bog?
I've got a feeling it's going to be a week where something may or may not happen. Like every other week.
When I see 'Got a feeling it's going to be a good week' I always think 'this AIM poster must know what they're on about, so I'd better get a decent wedge in here ASAP.'
NOT.
Agreed - that's quite enough of your sauce burble.
I was just concluding from your post that you see Scancell remaining independent for some 30 years, and the sp rising to 8 pounds. An interesting prediction, quite unlike many of your previous posts. We shall see.
So Ruck is now forecasting 8 pounds a share.
What a waste of space article. So in a year of renting a lab, they have no income from it (because if it was generating revenue that would have been mentioned more than an account of 'how we moved our stuff in a van'). More significant is what it didn't mention - revenue (because there is none) institutional investors (because there aren't any) trials in progress (none) noteworthy trial results (none, last one ended 5 years ago and not one promised peer review has appeared) and money available to further any work (none). It read more like a 'what I did in my summer holidays' kid's junior school essay than anything to do with a commercial company, written by a 'cutting edge' scientist...
I assume the change of auditors will be a disappointment to a select few who tentatively retained the idea of a problem in the accounts rather than (as stated) a problem with the auditors.
Fair comment WTP when you said '.. is Prof. Durrant finally(?) deciding to highlight the limitations of the personalised approach and push the advantages in the approach Scancell is taking.'
I suppose that while there has been a lot of head scratching wondering why LD hasn't trumpeted the advantages of Scancell science before, it now makes sense to push the science if they have the finical results to say 'and here's the proof in decent quantities', whereas prior to this it would have been more on the 'we hope' lines. Can we assume that 'we hope' is now 'we know' and 'here's the proof.'
Proof in human trials as you say, and an ORR that greatly exceeds the best in class, and substantially exceeds the target in the trial (so far, anyway - but great confidence from those running the trial that the ORR will maintain or increase as the numbers of patients rises, as I recall)
I'll second that Bermuda - the tone of information releases from the company have been consistent for so many years, never talking things up, and in fact as most of us are aware often seen as failing to capitalise on significant news which could have been used to generate greater publicity. This was especially frustrating to some as more 'sexed-up' news releases would have made for a more volatile share price and given more vocal trading opportunities for some of our departed or less visible friends. So assuming the level of reporting is consistent now as it has always been, this year could well be a lot more exciting than previous ones. LD has a reputation for calm delivery of news, I have no reason to think she suddenly wants to change that. Anyway, back to sitting and waiting. Time will tell as ever.
Wow! Was it 21 days they had to respond and did it in three! If only they were as prompt on a few other deadlines.